{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"139","value":"162.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"220"}],"units":"Participants"}],"description":"Cmax is the concentration at the end of a 1 hour infusion, corresponding to the maximum plasma concentration of avelumab. The LLQ of avelumab was 0.20 mcg/mL. Data for this outcome measure was not reported for reporting arms \"PK: Chemotherapy followed by Avelumab\" (data not available for this OM as avelumab was not given along with paclitaxel and carboplatin in this arm) and \"PK: Chemotherapy followed by Observation\" (since avelumab was not administered in this arm and therefore data collection was not planned).","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"In chemotherapy phase, participants received paclitaxel Q3W (or QW on Days 1, 8 and 15), followed by carboplatin Q3W along with avelumab Q3W on Day 1 of each 21 day cycle for 6 cycles. During the maintenance phase, participants received avelumab Q2W (on Days 1, 15 and 29 of each 42 day cycle).","id":"OG000","title":"PK: Chemotherapy + Avelumab Followed by Avelumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Avelumab PK concentration analysis set included all participants who had received at least one dose of study drug and who had at least one post-dose concentration measurement above the LLQ for avelumab. Here \"Overall number of participants analyzed\" signifies participants who had data available for this outcome measure.","reportingStatus":"POSTED","timeFrame":"End of infusion on Day 1 of Cycle 2","title":"Chemotherapy Phase: Maximum Plasma Concentration (Cmax) of Avelumab When Given With Paclitaxel and Carboplatin","type":"SECONDARY","unitOfMeasure":"mcg/mL"}